Back to Results
First PageMeta Content
Immune system / Targeted therapy / Cancer / CancerVax / Breast cancer treatment / Medicine / Immunology / Melanoma


PRESS RELEASE – IMMUNOCORE LIMITED Immunocore named one of Fierce 15 leading biotechs of[removed]Oxford, UK, 24 September[removed]Immunocore Limited, the Oxford-based biotechnology company developing novel biological drug
Add to Reading List

Document Date: 2013-09-24 03:45:28

Open Document

File Size: 141,15 KB

Share Result on Facebook

City

Abingdon / Oxford / /

Company

GlaxoSmithKline / Avidex Ltd / Roche Group / FierceBiotech / Immunocore 2 / IMMUNOCORE LIMITED / Genentech / ENDSContact Margaret Henry PR Consultant Immunocore Ltd / /

Country

United States / United Kingdom / /

/

Event

Business Partnership / /

Facility

University of Oxford / Immunocore laboratory / /

IndustryTerm

treatment of melanoma / biotechnology / receptor technology / treatment of cancer / platform technology / online newsletter / therapies for cancers / pharmaceutical / /

MedicalCondition

cancers / Melanoma cancer / cancer / viral infection / Immune mobilising mTCR Against Cancer / tumour / viral disease / melanoma / targeted cancer / kill cancer / /

Organization

Food and Drug Administration / Medicines and Healthcare products Regulatory Agency / University of Oxford / /

Person

Bent Jakobsen / James Noble / Ryan McBride / /

Position

Chief Executive Officer / Executive Editor / founder and chief scientist / /

Product

IMCgp100 / ImmTACs / /

Technology

ImmTAC technology / Cell Receptors / platform technology / biotechnology / Cell Receptor technology / T-cell receptor technology / /

URL

www.immunocore.com / http /

SocialTag